

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD
ON FRIDAY, 17 JUNE 2022**

References are made to the Notice (the “**Notice**”) of the annual general meeting (the “**AGM**”) and the circular (the “**Circular**”) of Mabpharm Limited (the “**Company**”) both dated 22 April 2022. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS

At the AGM of the Company held on Friday, 17 June 2022, all the proposed resolutions (the “**Proposed Resolutions**”) as set out in the Notice were duly passed by the Shareholders as ordinary resolutions or special resolutions (as the case maybe) by way of poll.

As at the date of the AGM, the total number of issued Shares was 4,124,080,000, which was the total number of shares entitling the Shareholders to attend and vote for or against the Proposed Resolutions at the AGM. None of the Shareholders were required under the Listing Rules to abstain from voting at the AGM. There were no shares entitling the Shareholders to attend and abstain from voting in favour at the AGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders have indicated in the Circular that they intended to vote against or to abstain from voting on any Proposed Resolutions at the AGM.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The Board of the Company is pleased to announce the poll results in respect of all the Proposed Resolutions at the AGM as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements and the reports of the directors and auditors for the year ended December 31, 2021.	3,747,131,500 (100%)	0 (0%)
2(a).	To re-elect Dr. Wang Hao as executive director.	3,747,131,500 (100%)	0 (0%)
2(b).	To re-elect Mr. Jiao Shuge as non-executive director.	3,747,131,500 (100%)	0 (0%)
2(c).	To appoint Mr. Leung, Louis Ho Ming as independent non-executive director and chairman of the audit committee under the board of directors to fill the vacancy due to Dr. Liu Linqing's retirement.	3,747,131,500 (100%)	0 (0%)
2(d).	To authorize the board of directors to fix directors' remuneration.	3,747,131,500 (100%)	0 (0%)
3.	To re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration.	3,747,131,500 (100%)	0 (0%)
4.	To grant a general mandate to the directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	3,747,131,500 (100%)	0 (0%)
5.	To grant a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	3,747,131,500 (100%)	0 (0%)
6.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company under resolution no. 5 above by the aggregate number of the shares repurchased by the Company.	3,747,131,500 (100%)	0 (0%)

Special Resolutions		Number of Votes (%)	
		For	Against
7.	The proposed amendments to the Memorandum and Articles of the Company be approved and adopted and the Directors be and are hereby authorised to do all such acts and things and execute all such documents and make all such arrangements as they shall, in their absolute discretion, deem necessary or expedient in connection with the implementation of or giving effect to the aforesaid adoption of the proposed amendments.	3,747,131,500 (100%)	0 (0%)

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions numbered 1 to 6, ordinary resolutions numbered 1 to 6 were duly passed as ordinary resolutions of the Company at the AGM.

As more than 75% of the votes were cast in favour of each of the above special resolutions numbered 7, special resolutions numbered 7 were duly passed as special resolutions of the Company at the AGM.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND THE CHAIRMAN OF AUDIT COMMITTEE

Following the conclusion of the AGM, Dr. Liu Linqing (“**Dr. Liu**”) will cease to be an independent non-executive Director and the chairman of audit committee (the “**Audit Committee**”) of the Company.

Dr. Liu has confirmed that he has no disagreement with the Board, and that he was not aware of other matters that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) in connection with his decision to resign.

The Board wishes to express its sincere gratitude to Dr. Liu for his valuable contribution to the Company during his tenure of services.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND THE CHAIRMAN OF AUDIT COMMITTEE

The Board is pleased to announce the appointment of Mr. Leung, Louis Ho Ming (“**Mr. Leung**”) as independent non-executive director and the chairman of Audit Committee with effect from 17 June 2022.

The biographical details of Mr. Leung are set out below:

Mr. Leung, Louis Ho Ming (“**Mr. Leung**”), aged 38, is a candidate for independent non-executive Director. Mr. Leung has been appointed as an independent non-executive Director and member of the audit committee and nomination committee and chairman of the remuneration committee of the GR Properties Limited (a company listed on the Main Board of the Stock Exchange with stock code: 108) since February 2020. Mr. Leung has been appointed as the financial controller and company secretary of AL Group Limited (a company listed on GEM of the Stock Exchange with stock code: 8360) since September 2019. Mr. Leung was a chief financial officer and company secretary of Prosperous Future Holdings Limited (formerly known as China Child Care Corporation Limited, a company listed on the Main Board of the Stock Exchange with stock code: 1259) from June 2017 to May 2019 and from January 2018 to May 2019 respectively.

Mr. Leung holds a bachelor degree of Science in Quantitative Finance from The Chinese University of Hong Kong in 2004. He has been a member of Hong Kong Institute of Certified Public Accountant since 2008 and has over 10 years of experience in accounting and auditing for Hong Kong listed and private companies.

Mr. Leung has entered into a service contract with the Company for an initial term of two years commencing on the date of the Annual General Meeting and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the Articles of Association. Under the service contract, Mr. Leung shall be entitled to a fixed Director’s fee of HK\$120,000 per year. His remuneration package has been determined by the Board on the recommendation of its Remuneration Committee by reference to his qualifications, experience and duties and responsibilities as well as the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Leung (i) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not have any relationship with other directors, senior management, substantial or controlling shareholders of the Company; (iii) did not have any interest or short positions in the shares of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong); (iv) there is no other information which is disclosable pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; and (v) there are no other matters in relation to the appointment of Mr. Leung that need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

The Board would like to welcome Mr. Leung on his appointment as independent non-executive director and the chairman of Audit Committee.

AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION

The Board hereby announces that the resolution on the proposed amendments to the existing memorandum and articles of association of the Company has been duly passed as a special resolution at the AGM. For details of the proposed amendments, please refer to Appendix III to the Circular.

The second amended and restated memorandum and articles of association of the Company will take effect from 17 June 2022, the full text of which is available on the websites of Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (www.mabpharm.cn).

By order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Shanghai, the PRC
June 17, 2022

As at the date of this announcement, the Board of Directors comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Mr. Leung, Louis Ho Ming as independent non-executive Directors.